Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Journal of Clinical Pharmacy and Therapeutics|March 5, 2008
No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipientsH Kagaya, M Miura, S Satoh, et al.
Prostate Cancer and Prostatic Diseases|October 13, 2004
Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer riskH Kakinuma, N Tsuchiya, T Habuchi, et al.
Journal of Clinical Pharmacy and Therapeutics|February 24, 2010
Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipientsM Miura, S Satoh, H Kagaya, et al.
Journal of Human Genetics|July 14, 2001
Definition of a 1-Mb homozygous deletion at 9q32-q33 in a human bladder-cancer cell lineH Fujiwara, M Emi, H Nagai, et al.
Cancer Genetics and Cytogenetics|May 30, 2001
BCL10 is not a major target for frequent loss of 1p in testicular germ cell tumorsH Kakinuma, T Habuchi, T Ito, et al.
International Journal of Cancer|February 20, 1993
Accumulated allelic losses in the development of invasive urothelial cancerT Habuchi, O Ogawa, Y Kakehi, et al.
Hinyokika Kiyo. Acta Urologica Japonica|March 1, 1988
[A case of paraureteral neurilemmoma causing ureteral obstruction: report of a case]S Yamamoto, H Onishi, T Habuchi, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 17, 2006
Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigenA Kataoka, T Yuasa, S Kageyama, et al.
Japanese Journal of Cancer Research : Gann|November 7, 1999
Two target regions of allelic loss on chromosome 9 in urinary-bladder cancerK Ohgaki, K Minobe, K Kurose, et al.
Pageof 8